Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Blair William & Co. IL

Blair William & Co. IL boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 589,067 shares of the biopharmaceutical company’s stock after buying an additional 12,984 shares during the period. Blair William & Co. IL’s holdings in Gilead Sciences were worth $42,772,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FSB Premier Wealth Management Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. OLD Second National Bank of Aurora grew its position in Gilead Sciences by 46.3% in the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 139 shares in the last quarter. Capital Advisors Ltd. LLC increased its stake in Gilead Sciences by 127.6% during the fourth quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 250 shares during the period. Dark Forest Capital Management LP acquired a new stake in shares of Gilead Sciences during the third quarter worth about $34,000. Finally, Central Bank & Trust Co. purchased a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $36,000. 80.16% of the stock is currently owned by institutional investors.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 3,634 shares of the firm’s stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a total transaction of $211,644.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

GILD traded up $0.66 on Wednesday, reaching $65.01. The company had a trading volume of 732,900 shares, compared to its average volume of 10,174,197. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $57.19 and a 1 year high of $74.12. The stock has a market capitalization of $81.54 billion, a PE ratio of 17.97, a P/E/G ratio of 0.45 and a beta of 0.38. The stock has a 50-day moving average price of $61.31 and a 200-day moving average price of $65.12.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.35. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.08 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 29th. Stockholders of record on Wednesday, June 15th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s payout ratio is currently 81.56%.

A number of research firms have issued reports on GILD. Mizuho reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “buy” rating on the stock in a report on Tuesday, February 8th. Piper Sandler decreased their target price on Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a report on Monday, May 16th. Wells Fargo & Company cut their price target on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 22nd. Truist Financial decreased their price objective on Gilead Sciences from $77.00 to $75.00 and set a “hold” rating for the company in a research note on Wednesday, February 2nd. Finally, Morgan Stanley cut their target price on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $72.20.

Gilead Sciences Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.